Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00138398 · ClinicalTrials.gov registry record · NA
T-cell Response-Flu Risk in Older Adults
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 850
- Enrollment target
NCT00138398 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 850 participants.
The verdict
NCT00138398, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 850 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how the immune system changes with aging and makes influenza a more serious illness in older people. Influenza vaccination not only can protect people from getting the flu but also can lessen the severity of the illness. This is particularly true for people with congestive heart failure (CHF). This research may provide information that could eventually lead to a new laboratory test that will predict how effective vaccination is for preventing influenza illness in older people. Volunteer participants in this study will include the following groups: 1) healthy young adults 20 - 40 years old; 2) older adults, 60 years and older, without a history of CHF; 3) older adults, 60 years and older, with a history of CHF. All study participants will be vaccinated with the current preparation of inactivated influenza vaccine. A small amount of blood will be drawn before each vaccine and at 4, 10, and 16-20 weeks afterward.
Interventions
- BIOLOGICAL Commercial TriValent Split Influenza Virus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2005-10-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00138398
The ClinicalTrials.gov registry entry for NCT00138398 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 850 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Commercial TriValent Split Influenza Virus is the first listed.
NCT00138398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00138398 about?
NCT00138398 is a clinical study titled "T-cell Response-Flu Risk in Older Adults". The purpose of this study is to determine how the immune system changes with aging and makes influenza a more serious illness in older people. Influenza vaccination not only can protect people from getting the flu but also can lessen the severity of the illness. This is particularly true for people ...
What is the current status of trial NCT00138398?
This trial is currently completed. It is a NA study. The enrollment target is 850 participants. The study started on 2005-10-25.
What interventions are being tested in trial NCT00138398?
The interventions under investigation include: Commercial TriValent Split Influenza Virus (BIOLOGICAL).
Who is sponsoring clinical trial NCT00138398?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.